Loading clinical trials...

A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients | Clinical Trials | Clareo Health

RECRUITING

A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients

A Prospective Observational Study to the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients

NCT06118229•The First Affiliated Hospital of Guangzhou Medical University

View on ClinicalTrials.gov

Summary

The trial was designed as a single-center non-interventional prospective observational study to explore the role and impact of wearable smart devices in perioperative NSCLC patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participants must provide voluntary consent to participate in this research and possess the capacity to sign an informed consent form.
•2. Participants must be aged over 18 years.
•3. Participants must have undergone pulmonary resection surgery with a postoperative pathological confirmation of primary lung cancer.

Exclusion Criteria

•1. Patient refusal to participate in this research.
•2. Inability to wear wearable smart monitoring devices due to various reasons.
•3. The pathological report suggests a non-small cell lung cancer (NSCLC) exclusion.
•4. History of secondary lung cancer surgery.

Locations (1)

Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Key Dates

Start Date

March 9, 2023

Primary Completion Date

July 31, 2024

Completion Date

March 31, 2026

Last Updated

June 28, 2024

Enrollment

300

ESTIMATED participants

Conditions

Non Small Cell Lung Cancer

Interventions

Wearable smart devices and PROs

DEVICE

Contacts

Jianxing He, M.D

CONTACT

+86-20-83337792 drjianxing.he@gmail.com

Wenhua Liang, M.D

CONTACT

+86-13710249454 liangwh1987@163.com

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)